What is the recommended first‑line therapy for bacterial vaginosis in an adult woman, and what alternative regimens are used if metronidazole is contraindicated or for recurrent infection?

Bacterial Vaginosis Treatment

First-Line Therapy

Oral metronidazole 500 mg twice daily for 7 days is the preferred first-line treatment for bacterial vaginosis, achieving approximately 95% cure rates. 1

Alternative first-line regimens with comparable efficacy include:

• Metronidazole gel 0.75% (5 g applicator) intravaginally once daily for 5 days, with cure rates of 70–84% 1, 2
• Clindamycin cream 2% (5 g applicator) intravaginally at bedtime for 7 days, achieving 82–86% cure rates 1, 2

Critical Patient Counseling

Patients taking oral metronidazole must avoid all alcohol during therapy and for 24 hours after the final dose to prevent disulfiram-like reactions (flushing, nausea, vomiting, tachycardia). 1

Clindamycin cream is oil-based and will weaken latex condoms and diaphragms; patients must use alternative contraception during treatment and for several days afterward. 1

---

Alternative Regimens (Lower Efficacy)

When the standard 7-day course is not feasible:

• Metronidazole 2 g orally as a single dose achieves approximately 84% cure rate—inferior to the 7-day regimen but may improve adherence in select patients 1, 2
• Clindamycin ovules 100 mg intravaginally once nightly for 3 days (alternative option with shorter duration) 2
• Oral clindamycin 300 mg twice daily for 7 days achieves 93.9% cure rate and is appropriate when oral therapy is preferred over topical agents 1

---

Treatment When Metronidazole Is Contraindicated

True Metronidazole Allergy

For patients with confirmed metronidazole allergy, clindamycin cream 2% (5 g) intravaginally at bedtime for 7 days is the recommended alternative. 1

• Oral clindamycin 300 mg twice daily for 7 days is equally effective (93.9% cure rate) 1
• Never prescribe metronidazole gel to patients with true metronidazole allergy—topical formulations can still trigger systemic allergic reactions despite minimal absorption 1

Metronidazole Intolerance (Not True Allergy)

For patients who cannot tolerate systemic metronidazole due to gastrointestinal side effects:

• Metronidazole gel 0.75% produces peak serum concentrations <2% of oral doses, markedly reducing systemic side effects while maintaining local efficacy 1

---

Recurrent Bacterial Vaginosis

Initial Recurrence

For first recurrence after standard therapy, switch to oral clindamycin 300 mg twice daily for 7 days or intravaginal clindamycin 2% cream nightly for 7 days, both achieving cure rates exceeding 90%. 3

Multiple Recurrences

For women experiencing multiple recurrences (≥3 episodes within 12 months):

• Extended metronidazole course: 500 mg orally twice daily for 10–14 days 4
• If ineffective, metronidazole gel 0.75% for 10 days, followed by twice weekly for 3–6 months as suppressive therapy 4
• Recurrence affects approximately 50% of women within 1 year of treatment for incident disease 4

---

Special Populations

Pregnancy

First Trimester:

• Clindamycin vaginal cream 2% is the only recommended treatment, as metronidazole is contraindicated 1, 2

Second and Third Trimesters:

• Metronidazole 250 mg orally three times daily for 7 days (lower dose to minimize fetal exposure) 1
• For high-risk pregnant women (prior preterm delivery), systemic therapy is preferred over topical to address possible subclinical upper genital tract infection 1, 5

Breastfeeding

Oral clindamycin 300 mg twice daily for 7 days is compatible with breastfeeding and achieves 93.9% cure rates. 1

---

Asymptomatic Bacterial Vaginosis: When to Treat

Do not treat asymptomatic BV in non-pregnant women unless they are undergoing specific high-risk procedures. 1

Mandatory Treatment Indications:

• Before surgical abortion—metronidazole substantially reduces post-abortion pelvic inflammatory disease 1
• Before hysterectomy—reduces postoperative infectious complications by 10–75% 1
• Consider treatment before endometrial biopsy, hysterosalpingography, IUD placement, cesarean section, or uterine curettage (BV associated with endometritis, PID, and vaginal cuff cellulitis after these procedures) 1

High-Risk Pregnant Women:

Women with prior preterm delivery who have asymptomatic BV may be evaluated for treatment, as it might reduce prematurity risk. 1

---

Partner Management

Do not treat male sexual partners—multiple randomized controlled trials demonstrate that partner treatment does not improve cure rates, reduce recurrence, or affect therapeutic response. 1, 3

---

Sexual Activity During Treatment

Patients should abstain from sexual intercourse until the entire antimicrobial course is finished:

• For 7-day regimens: abstain for the full 7 days of therapy 1
• For single-dose metronidazole: abstain for 7 days following the dose 1

---

Follow-Up Recommendations

Routine follow-up visits are unnecessary if symptoms resolve completely. 1, 3

Exception: High-risk pregnant patients should have follow-up evaluation at 1 month after therapy completion to confirm cure. 2

---

Common Pitfalls to Avoid

• Do not use single-dose metronidazole 2 g as first-line therapy—its 84% cure rate is inferior to the 95% cure rate of the 7-day regimen 1
• Do not culture for Gardnerella vaginalis—it can be isolated from half of normal women and is not specific for BV 1
• Do not prescribe prophylactic fluconazole with metronidazole therapy; antifungal treatment should be reserved for patients who develop symptomatic candidiasis 1
• Do not assume metronidazole is teratogenic in humans—recent meta-analyses confirm its safety for fetal exposure despite animal data at very high doses 1